Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
NCT04939818
Alzheimer Disease, Amyotrophic Lateral Sclerosis
London, Greater London, United Kingdom
View Trial DetailsNCT Number: NCT02050464
The Virtual Physiological Human: DementiA Research Enabled by IT (VPH-DARE@IT) is a four-year IT-project funded through the European Union (EU). The project consortium involves a total of 21 universities and industrial partners from 10 European countries. The project delivers the first patient-specific predictive models for early differential diagnosis of dementia and their evolution. An integrated clinical decision support platform will be validated / tested by access to a dozen databases of international cross-sectional and longitudinal studies. As a part of the VPH-DARE@IT project, a new prospective cohort will be collected in Kuopio. This prospective cohort will be used to test further the modeling approaches and tools developed by using the retrospective databases.
Looking for future studies?
Notify Me50 year–85 year
All sexes
Observational
Department of Neurology and Brain Research Unit, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
The Virtual Physiological Human: DementiA Research Enabled by IT (VPH-DARE@IT) is a four-year IT-project funded through the European Union (EU). The project will develop multiscale models of the ageing brain in order to account simultaneously for the patient-specific biochemical, metabolic and biomechanical brain substrate, as well as for genetic, clinical, demographic and lifestyle determinants. An integrated clinical decision support platform will be validated and tested by access to a dozen databases of international cross-sectional and longitudinal studies.
Modeling approaches developed by using the retrospective databases will be tested using a new prospective cohort that will be collected in Kuopio as a part of the VPH-DARE@IT project. The study population at university of Eastern Finland (UEF) will be a total of 120 subjects: 20 healthy controls (HC), 20 mild to moderate Alzheimer's disease (AD) patients, 20 vascular dementia (VAD) patients, 20 fronto-temporal dementia (FTD) patients and 40 subjects with mild cognitive impairment (MCI). This study is referred as VPH-DARE@IT Prospective study in Kuopio or "ProsKuopio".
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for subjects with dementia (AD, VAD, FTD) - The inclusion criteria will be based on international research criteria:
Inclusion criteria
for subjects with MCI
Inclusion criteria
for control subjects
Exclusion criteria
Exclusion criteria
for all subjects
Exclusion criteria
for control subjects and subjects with MCI
Time frame: during a single visit, i.e., day 1 and for one study group (MCI) after 18 month follow-up
The models developed the VPH-DARE project will be tested in this prospective cohort. Sensitivity, specificity and accuracy of the model will be tested in differential diagnosis between the study groups as well as the accuracy of prediction cognitive decline as measured by neuropsychological test battery in the MCI group.
University of Eastern Finland
Other
Virtual Physiological Human (VPH) Dementia Research Enabled by IT - Prospective Cohort Kuopio
Acronym: ProsKuopio
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04939818
Alzheimer Disease, Amyotrophic Lateral Sclerosis
London, Greater London, United Kingdom
View Trial DetailsNCT03682185
Aberrant Motor Behavior in Dementia, Alzheimer Disease
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04157244
Alzheimer Disease, Arterial Occlusive Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06529744
Alzheimer Disease, Aphasia
North York, Ontario, Canada
View Trial Details